ES2044825T3 - Formulaciones de matriz de liberacion retardada. - Google Patents

Formulaciones de matriz de liberacion retardada.

Info

Publication number
ES2044825T3
ES2044825T3 ES88301684T ES88301684T ES2044825T3 ES 2044825 T3 ES2044825 T3 ES 2044825T3 ES 88301684 T ES88301684 T ES 88301684T ES 88301684 T ES88301684 T ES 88301684T ES 2044825 T3 ES2044825 T3 ES 2044825T3
Authority
ES
Spain
Prior art keywords
release
polymer
sustained release
hydrophilic polymer
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301684T
Other languages
English (en)
Other versions
ES2044825T1 (es
Inventor
Peter Lloyd Oren
Werner Max Karl Seidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2044825T1 publication Critical patent/ES2044825T1/es
Application granted granted Critical
Publication of ES2044825T3 publication Critical patent/ES2044825T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

ESTA INVENCION PROPORCIONA UNA COMPOSICION MATRIZ PARA LIBERACION SOSTENIDA DE FARMACOS, QUE ESTA FORMADA POR UN AGENTE ACTIVO, UN POLIMERO HIDROFILICO Y UN POLIMERO ENTERICO. ESTE ULTIMO ES IMPERMEBALE A LOS FLUIDOS GASTRICOS Y AYUDA A RETARDAR LA LIBERACION DEL FARMACO EN REGIONES DE PH BAJO, PERMITIENDO ASI EMPLEAR NIVELES MAS BAJOS DE POLIMERO HIDROFILICO. EN LA GAMA DE PH DE LOS FLUIDOS INTESTINALES, ESTE POLIMERO SE DISOLVERA Y AUMENTARA ASI LA PERMEABILIDAD DE LA FORMA DE DOSIFICACION. ESTE PROCEDIMIENTO ES UTIL PARA PROLONGAR LA LIBERACION DE NUMEROSOS AGENTES ACTIVOS CUYA SOLUBILIDAD DISMINUYE AL AUMENTAR EL PH, UNA CARACTERISTICA DE FARMACOS DEBILMENTE BASICOS. ESTAS FORMAS DE DOSIFICACION DE LIBERACION SOSTENIDA QUE RESPONDEN A CAMBIOS EN EL PH FISIOLOGICO, TIENEN UN COMPORTAMIENTO ACEPTABLE, A PESAR DE LA VARIABILIDAD EN LOS TIEMPOS DE TRANSITO GASTROINTESTINAL DE LA FORMULACION.
ES88301684T 1987-02-27 1988-02-26 Formulaciones de matriz de liberacion retardada. Expired - Lifetime ES2044825T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1991587A 1987-02-27 1987-02-27

Publications (2)

Publication Number Publication Date
ES2044825T1 ES2044825T1 (es) 1994-01-16
ES2044825T3 true ES2044825T3 (es) 1994-11-16

Family

ID=21795732

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301684T Expired - Lifetime ES2044825T3 (es) 1987-02-27 1988-02-26 Formulaciones de matriz de liberacion retardada.

Country Status (26)

Country Link
EP (1) EP0280571B1 (es)
JP (1) JPH082793B2 (es)
KR (1) KR960005140B1 (es)
CN (1) CN1023765C (es)
AR (1) AR243376A1 (es)
AT (1) ATE92309T1 (es)
AU (1) AU604849B2 (es)
CA (1) CA1316110C (es)
CY (1) CY1741A (es)
DE (2) DE3882739T2 (es)
DK (1) DK175620B1 (es)
EG (1) EG18523A (es)
ES (1) ES2044825T3 (es)
GR (1) GR930300027T1 (es)
HK (1) HK125793A (es)
HU (1) HU202747B (es)
IE (1) IE61419B1 (es)
IL (1) IL85538A (es)
LV (1) LV10184B (es)
MX (1) MX10558A (es)
NZ (1) NZ223619A (es)
PH (1) PH24358A (es)
PT (1) PT86831B (es)
RU (1) RU1831337C (es)
UA (1) UA18251A (es)
ZA (1) ZA881301B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048133T3 (es) * 1990-05-04 2000-01-16 Perio Prod Ltd Sistema de descarga de farmacos para el colon.
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
FR2667242B1 (fr) * 1990-09-28 1994-11-25 Rhone Poulenc Sante Nouvelles formes orales a liberation prolongee avec un temps de latence au niveau stomacal amoindri.
IT1250654B (it) * 1991-07-08 1995-04-21 Farcon Ag Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
EP0724886A4 (en) * 1993-10-22 1996-11-06 Tsumura & Co BASE FOR A DELAYED-RELEASE PREPARATION, DELAYED-RELEASE PREPARATION AND METHOD FOR PRODUCING THIS PREPARATION
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ES2206709T3 (es) * 1996-05-13 2004-05-16 Novartis Consumer Health S.A. Sistema de suministro bucal.
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
ATE232728T1 (de) * 1998-03-03 2003-03-15 Dae Woong Pharma Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
US6734157B2 (en) 1999-12-28 2004-05-11 Kimberly-Clark Worldwide, Inc. Controlled release anti-microbial hard surface wiper
AU774993B2 (en) 1999-12-28 2004-07-15 Kimberly-Clark Worldwide, Inc. Use-dependent indicator system for absorbent articles
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
EP1330250B1 (en) 2000-10-30 2004-05-12 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
WO2004062577A2 (en) 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
DE102005019458A1 (de) 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US7722898B2 (en) 2006-04-26 2010-05-25 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
JP5245175B2 (ja) * 2006-11-13 2013-07-24 杏林製薬株式会社 持続放出型錠剤の製造方法
US20120029032A1 (en) 2009-03-27 2012-02-02 Kyorin Pharmaceutical Co., Ltd. Matrix-type sustained release preparation containing basic additive
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CN101912373B (zh) * 2010-08-24 2012-01-04 北京京丰制药有限公司 稳定的头孢克洛分散片及其制备方法
KR20170015315A (ko) * 2014-06-10 2017-02-08 라이온 가부시키가이샤 청주 효모를 함유하는 정제
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151913B (es) * 1980-01-11 1983-09-03 Boots Co Ltd
JPS6024765B2 (ja) * 1981-11-27 1985-06-14 辰巳化学株式会社 セフアレキシンの持続性製剤の製造方法
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
LU85058A1 (fr) * 1983-10-24 1985-06-19 Pharlyse Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
US4520009A (en) * 1983-11-28 1985-05-28 Verex Laboratories, Inc. Sustained released aspirin formulation
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法

Also Published As

Publication number Publication date
AU1219388A (en) 1988-09-01
JPS63227519A (ja) 1988-09-21
PT86831B (pt) 1992-05-29
DK98088D0 (da) 1988-02-25
DK98088A (da) 1988-08-28
IE61419B1 (en) 1994-11-02
LV10184A (lv) 1994-10-20
DE280571T1 (de) 1993-08-12
GR930300027T1 (es) 1993-05-24
CN1023765C (zh) 1994-02-16
ZA881301B (en) 1989-10-25
LV10184B (en) 1995-04-20
EP0280571B1 (en) 1993-08-04
DE3882739T2 (de) 1994-02-17
KR880009639A (ko) 1988-10-04
UA18251A (uk) 1997-12-25
RU1831337C (ru) 1993-07-30
HU202747B (en) 1991-04-29
AR243376A1 (es) 1993-08-31
HK125793A (en) 1993-11-19
NZ223619A (en) 1990-10-26
DE3882739D1 (de) 1993-09-16
EP0280571A3 (en) 1989-01-04
DK175620B1 (da) 2004-12-27
KR960005140B1 (ko) 1996-04-22
MX10558A (es) 1993-11-01
EG18523A (en) 1993-04-30
PH24358A (en) 1990-06-13
CN88101062A (zh) 1988-09-07
AU604849B2 (en) 1991-01-03
IE880545L (en) 1988-08-27
CA1316110C (en) 1993-04-13
HUT46531A (en) 1988-11-28
ES2044825T1 (es) 1994-01-16
CY1741A (en) 1995-02-17
IL85538A (en) 1991-09-16
PT86831A (pt) 1988-03-01
EP0280571A2 (en) 1988-08-31
ATE92309T1 (de) 1993-08-15
IL85538A0 (en) 1988-08-31
JPH082793B2 (ja) 1996-01-17

Similar Documents

Publication Publication Date Title
ES2044825T3 (es) Formulaciones de matriz de liberacion retardada.
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
Makwana et al. Advancements in controlled release gastroretentive drug delivery system: A review
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
Roge et al. The enkephalinase inhibitor, acetorphan, in acute diarrhoea: a double-blind, controlled clinical trial versus loperamide
ES2112387T3 (es) Composiciones farmaceuticas que contienen simeticona para el tratamiento de problemas gastrointestinales.
EA200300045A1 (ru) Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
CO5570652A2 (es) Productos en gel para la axila, con componente de bloqueo de agua
AR036747A1 (es) Productos para la axila, con componente de bloque de agua
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
PT96921B (pt) Dispositivo de libertacao intermitente
AR002049A1 (es) Una composicion farmaceutica para la administracion oral de agentes activos que tienen baja solubilidad en agua y el procedimiento para prepararla
Rajak et al. Gastroretentive floating drug delivery system: an approach in gastroretentive drug delivery
DE60041691D1 (de) Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
Aslam et al. Techniques and polymers used to design Gastroretentive drug delivery systems–a review
AR022338A1 (es) Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
ES2266489T3 (es) Constructo farmaceutico de liberacion para retencion gastrica.
Bhowmik et al. Gastro Retentive Drug Delivery Systems-a Novel Approaches of Controlled Drug Delivery Systems
ES2673275T3 (es) Composición tópica que comprende un agente antibacteriano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 280571

Country of ref document: ES